Journal
BIOMACROMOLECULES
Volume 16, Issue 11, Pages 3425-3433Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.biomac.5b00643
Keywords
-
Funding
- Agence Nationale de la Recherche (grant DENDRI'MS) [ANR-RPIB-2011-005]
- Association pour la Recherche sur la Sclerose en Plaques (ARSEP)
- Institut National de la Sante et de la Recherche Medicale (INSERM)
- Centre National de la Recherche Scientifique (CNRS)
- University of Toulouse
Ask authors/readers for more resources
Dendrimers are polyfunctional nano-objects of perfectly defined structure that can provide innovative alternatives for the treatment of chronic inflammatory diseases, including multiple sclerosis (MS). To investigate the efficiency of a recently described amino-bis(methylene phosphonate)capped ABP dendrimer as a potential drug candidate for MS, we used the classical mouse model of MOG(35-55)-induced experimental autoimmune encephalomyelitis (EAR). Our study provides evidence that the ABP dendrirner prevents the development of EAR and inhibits the progression of established disease with a comparable therapeutic benefit as the approved treatment Fingolimod. We also show that the ABP dendrimer redirects the pathogenic myelin-specific CD4(+) T cell response toward IL-10 production.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available